ArticleBMC immunology2010
The antigen presentation function of bone marrow-derived mast cells is spatiotemporally restricted to a subset expressing high levels of cell surface FcepsilonRI and MHC II.
Article in BMC immunology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 36 citations in OpenAlex.
- Conventional and non-conventional antigen presentation by mast cells.Discovery immunology · 2023Review
- Mast Cells May Regulate The Anti-Inflammatory Activity of IL-37.International journal of molecular sciences · 2019Review
- Mast Cells, Stress, Fear and Autism Spectrum Disorder.International journal of molecular sciences · 2019Review
- Recent advances in our understanding of mast cell activation - or should it be mast cell mediator disorders?Expert review of clinical immunology · 2019Review
- Role of Mast Cells in Regulation of T Cell Responses in Experimental and Clinical Settings.Clinical reviews in allergy & immunology · 2018Review
- Article
- Is cancer a severe delayed hypersensitivity reaction and histamine a blueprint?Clinical and translational medicine · 2016Article
- Functions of Exosomes and Microbial Extracellular Vesicles in Allergy and Contact and Delayed-Type Hypersensitivity.International archives of allergy and immunology · 2016Review
- IL-33 promotes MHC class II expression in murine mast cells.Immunity, inflammation and disease · 2015Article
- Mast Cells as Regulators of T Cell Responses.Frontiers in immunology · 2015Review
- Atypical MHC class II-expressing antigen-presenting cells: can anything replace a dendritic cell?Nature reviews. Immunology · 2014Review
- Stress triggers coronary mast cells leading to cardiac events.Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology · 2014Review
- Mast cell-directed recruitment of MHC class II positive cells and eosinophils towards mesenteric lymphatic vessels in adulthood and elderly.Lymphatic research and biology · 2014Article
- Animal models for IgE-meditated cancer immunotherapy.Cancer immunology, immunotherapy : CII · 2012Review
- Targeting HER2/neu with a fully human IgE to harness the allergic reaction against cancer cells.Cancer immunology, immunotherapy : CII · 2012Article
- Mast cells and inflammation.Biochimica et biophysica acta · 2012Review
- Human mast cell degranulation and preformed TNF secretion require mitochondrial translocation to exocytosis sites: relevance to atopic dermatitis.The Journal of allergy and clinical immunology · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 2 countries.
Funding
Abstract
backgroundAt present, it is highly controversial whether pure mast cells can serve as antigen presenting cells, and it is not known whether the capacity of antigen presenting function is temporally restricted to a particular subset of differentiated mast cells. Evidence is presented for a novel surface FcepsilonRIhi , MHC II +, and c-kit + pure mast cell subset, temporally restricted as antigen-presenting cells in the immune axis of T-cell activation.
resultsBone marrow-derived mast cells (BMMC) cultured in the presence of IL-3 for three weeks are pure mast cells based on surface expression of lineage-specific marker, c-kit and FcepsilonRI. Herein we present the first demonstration that approximately 98.7% c-kit + and FcepsilonRI expressing BMMC, further depleted of any contaminated professional antigen-presenting cells, are still fully capable of presenting antigens, i.e., OVA protein, OVA peptide, and IgE-TNP-OVA, to OVA peptide-specific T-cell hybridomas. Notably, IgE-dependent antigen presentation is more efficient compared to that resulting from direct antigen uptake. Importantly, we present the novel finding that only surface FcepsilonRIhi mast cells, also expressing surface MHC II exhibited antigen-presenting function. In contrast, surface FcepsilonRIlo mast cells without expressing surface MHC II were not capable of antigen presentation. Interestingly, the antigen-presenting function of BMMC was irrevocably lost during the third and fourth week in IL-3 or SCF containing cultures.
conclusionsThis is the first observation to attribute a spatiotemporally restricted antigen-presenting function to a subset of three-week old pure BMMC expressing both high levels of surface FcepsilonRI and surface MHC II. We propose that mast cells play an important role in immune deviating and/or sustaining the activation of infiltrating CD4 T-cells, and modulating T-cell mediated allergic inflammation via its flexibility to present antigens and antigen-IgE complexes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.